C4 Therapeutics Inc. (CCCC) News
Filter CCCC News Items
CCCC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CCCC News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CCCC News From Around the Web
Below are the latest news stories about C4 THERAPEUTICS INC that investors may wish to consider to help them evaluate CCCC as an investment opportunity.
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceWATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that Andrew Hirsch, president and chief executive officer of C4T, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PST (5:15 pm EST). The presentation will be webcast live and may be accessed through C4T’s website on the Even |
Here's Why C4 Therapeutics (CCCC) Is a Great 'Buy the Bottom' Stock NowC4 Therapeutics (CCCC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
Why C4 Therapeutics (CCCC) Is One of the Best Biotech Penny Stocks to Invest in Now?We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a look at where C4 Therapeutics, Inc. (NASDAQ:CCCC) stands against the other best biotech penny stocks to invest in now. Goldman Sachs has spotlighted an often-overlooked sector poised to benefit from […] |
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 DegraderIn Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels Multiple Myeloma Arm Demonstrated Well-Tolerated Safety Profile; On-Target Neutropenia Was Manageable With Low Rates of Febrile Neutropenia and Infections; No Treatment Emergent Adverse Events Leading to Dose Reduction In Non-Hodgkin’s Lymphoma, Cemsidomide Monoth |
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of DirectorsHoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Steve Hoerter |
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical TrialClinical Development Initiated in Greater China by Partner Betta PharmaceuticalsWATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced its partner Betta Pharmaceuticals has dosed the first patient in the Phase 1 clinical trial of CFT8919, an orally bioavailable allosteric degrader of EGFR L858R for non-small cell lung cancer (NSCLC), in |
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual MeetingC4T to Host Webcast on Sunday, December 8, 2024 at 2 PM PT (5 PM ET)WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that two abstracts from the ongoing Phase 1/2 trial of cemsidomide have been accepted for presentation at the ASH Annual Meeting taking place from December 7 – 10, 2024 in San Diego, California. Non-Hodgkin’s lymphom |
C4 Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsC4 Therapeutics ( NASDAQ:CCCC ) Third Quarter 2024 Results Key Financial Results Revenue: US$15.4m (up 39% from 3Q... |
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue EstimatesC4 Therapeutics (CCCC) delivered earnings and revenue surprises of 12.50% and 158.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsCemsidomide Phase 1/2 Trial in Multiple Myeloma and non-Hodgkin’s Lymphoma Continues to Progress: Data from Both Indications to be Presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA Initial Monotherapy CFT1946 Phase 1 Data Demonstrated Well-Tolerated Safety Profile and Early Evidence of Anti-tumor Activity; Phase 1/2 Trial Continues to Progress with Multiple Data Readouts Expected in 2025 Appointed Paige Mahaney, Ph.D. as Chief Scientific Officer Bringing |